Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medytoxin in Benign Masseteric Hypertrophy
NCT02292472Phase 2Completed
- Sponsor
- Medytox Inc.
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of neuronox in benign masseteric hypertrophy (BMH), sponsored by Medytox Inc.. Started Oct 2014; status: completed.
02
Drugs
neuronox
03
Conditions
benign masseteric hypertrophy (BMH)
Beyond the preview
Go deeper on NCT02292472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292472.